Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779675 | 0.93 | S1PR3 (0.53) | MAPTKDM4EPKMS1PR3ALDH1A1 | |
| SCHEMBL3846423 | 0.80 | ROCK2 (0.43) | MAPTS1PR3TP53 | |
| SCHEMBL3847524 | 0.80 | FAAH (0.54) | MAPTKDM4EPKMTP53FAAH | |
| SCHEMBL2168842 | 0.75 | FAAH (0.64) | MAPTKDM4EPKMTP53FAAH | |
| SCHEMBL2160503 | 0.75 | FAAH (0.50) | MAPTKDM4EPKMTP53FAAH | |
| SCHEMBL14972825 | 0.74 | MAPT (0.47) | MAPTKDM4EPKMTP53FAAH | |
| SCHEMBL14972847 | 0.73 | MAPT (0.47) | MAPTKDM4EPKMTP53FAAH | |
| SCHEMBL6255149 | 0.72 | TUBB4A (0.48) | MAPTTP53FAAHMEN1KMT2A | |
| SCHEMBL2162522 | 0.71 | MAPT (0.64) | MAPTKDM4EPKMS1PR3TP53 | |
| SCHEMBL3001909 | 0.71 | FAAH (0.68) | MAPTFAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | BAXTER HEALTHCARE S.A. (CH) | 2003-11-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | MAPT 3185/4885KDM4E 1023/4885PKM 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.